The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Company: Rosetta Genomics
Other products in this section:
Why even a moth’s brain is smarter than an AI
A neural network that simulates the way moths recognize odors also shows how they learn so much faster than machines.
In the future we won’t edit genomes—we’ll just print out new ones
Why redesigning the humble yeast could kick off the next industrial revolution.
Gene-altering treatments are medicine’s best shot yet against Huntington’s disease
After 25 years, scientists are starting to make progress against the devastating illness.